Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
| العنوان: | Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia |
|---|---|
| المؤلفون: | Nicholas J. Short, Keyur P. Patel, Farhad Ravandi, Marisa J. L. Aitken |
| المصدر: | Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-15 (2021) Journal of Hematology & Oncology |
| بيانات النشر: | BMC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Neoplasm, Residual, Measurable residual disease, medicine.medical_treatment, Disease, Review, Maintenance therapy, Internal medicine, hemic and lymphatic diseases, Medicine, Animals, Humans, Diseases of the blood and blood-forming organs, Molecular Biology, RC254-282, Hematology, Acute myeloid leukemia, business.industry, Surrogate endpoint, Hematopoietic Stem Cell Transplantation, Hematopoietic stem cell, Myeloid leukemia, Disease Management, High-Throughput Nucleotide Sequencing, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunotherapy, Flow Cytometry, Prognosis, Clinical trial, body regions, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Karyotyping, RC633-647.5, business |
| الوصف: | Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in their sensitivity and applicability to individual patients. MRD detected by quantitative polymerase chain reaction, multiparameter flow cytometry, or next-generation sequencing has prognostic implications in various subsets of AML and at various times throughout treatment. While it is overwhelmingly evident that minute levels of remnant disease confer increased risk of relapse and shortened survival, the therapeutic implications of MRD remain less clear. The use of MRD as a guide to selecting the most optimal post-remission therapy, including hematopoietic stem cell transplant or maintenance therapy with hypomethylating agents, small molecule inhibitors, or immunotherapy is an area of active investigation. In addition, whether there are sufficient data to use MRD negativity as a surrogate endpoint in clinical trial development is controversial. In this review, we will critically examine the methods used to detect MRD, its role as a prognostic biomarker, MRD-directed therapeutics, and its potential role as a study endpoint. |
| اللغة: | English |
| تدمد: | 1756-8722 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab227a324d7c028b89c350a392031eeb https://doaj.org/article/c67c87fda4294a258d5d00f818a07cc0 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ab227a324d7c028b89c350a392031eeb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17568722 |
|---|